These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23822179)

  • 1. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
    Moreno-Sanz G; Duranti A; Melzig L; Fiorelli C; Ruda GF; Colombano G; Mestichelli P; Sanchini S; Tontini A; Mor M; Bandiera T; Scarpelli R; Tarzia G; Piomelli D
    J Med Chem; 2013 Jul; 56(14):5917-30. PubMed ID: 23822179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
    Moreno-Sanz G; Barrera B; Armirotti A; Bertozzi SM; Scarpelli R; Bandiera T; Prieto JG; Duranti A; Tarzia G; Merino G; Piomelli D
    Pharmacol Res; 2014 Sep; 87():87-93. PubMed ID: 24993496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.
    Tarzia G; Duranti A; Tontini A; Piersanti G; Mor M; Rivara S; Plazzi PV; Park C; Kathuria S; Piomelli D
    J Med Chem; 2003 Jun; 46(12):2352-60. PubMed ID: 12773040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
    Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
    J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
    Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
    J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
    Tarzia G; Duranti A; Gatti G; Piersanti G; Tontini A; Rivara S; Lodola A; Plazzi PV; Mor M; Kathuria S; Piomelli D
    ChemMedChem; 2006 Jan; 1(1):130-9. PubMed ID: 16892344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
    Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
    J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase suppress the development and maintenance of paclitaxel-induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro.
    Slivicki RA; Xu Z; Mali SS; Hohmann AG
    Pharmacol Res; 2019 Apr; 142():267-282. PubMed ID: 30739035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
    Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
    J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
    Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
    Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
    Naidu PS; Booker L; Cravatt BF; Lichtman AH
    J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-(triazolyl)methyl carbamates as a novel and potent class of fatty acid amide hydrolase (FAAH) inhibitors.
    Colombano G; Albani C; Ottonello G; Ribeiro A; Scarpelli R; Tarozzo G; Daglian J; Jung KM; Piomelli D; Bandiera T
    ChemMedChem; 2015 Feb; 10(2):380-95. PubMed ID: 25338703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies.
    Käsnänen H; Myllymäki MJ; Minkkilä A; Kataja AO; Saario SM; Nevalainen T; Koskinen AM; Poso A
    ChemMedChem; 2010 Feb; 5(2):213-31. PubMed ID: 20024981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.
    Moreno-Sanz G; Barrera B; Guijarro A; d'Elia I; Otero JA; Alvarez AI; Bandiera T; Merino G; Piomelli D
    Pharmacol Res; 2011 Oct; 64(4):359-63. PubMed ID: 21767647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
    Mor M; Lodola A; Rivara S; Vacondio F; Duranti A; Tontini A; Sanchini S; Piersanti G; Clapper JR; King AR; Tarzia G; Piomelli D
    J Med Chem; 2008 Jun; 51(12):3487-98. PubMed ID: 18507372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
    Gattinoni S; Simone CD; Dallavalle S; Fezza F; Nannei R; Battista N; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4406-11. PubMed ID: 20591666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood-placenta barrier.
    Moreno-Sanz G; Sasso O; Guijarro A; Oluyemi O; Bertorelli R; Reggiani A; Piomelli D
    Br J Pharmacol; 2012 Dec; 167(8):1620-8. PubMed ID: 22774772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
    Korhonen J; Kuusisto A; van Bruchem J; Patel JZ; Laitinen T; Navia-Paldanius D; Laitinen JT; Savinainen JR; Parkkari T; Nevalainen TJ
    Bioorg Med Chem; 2014 Dec; 22(23):6694-6705. PubMed ID: 25282655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain.
    Jiang HX; Ke BW; Liu J; Ma G; Hai KR; Gong DY; Yang Z; Zhou C
    Anesth Analg; 2019 Aug; 129(2):587-597. PubMed ID: 29863609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral FAAH inhibition causes profound antinociception and protects against indomethacin-induced gastric lesions.
    Sasso O; Bertorelli R; Bandiera T; Scarpelli R; Colombano G; Armirotti A; Moreno-Sanz G; Reggiani A; Piomelli D
    Pharmacol Res; 2012 May; 65(5):553-63. PubMed ID: 22420940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.